Rhumbline Advisers Sells 39,739 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Rhumbline Advisers lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,323,602 shares of the biopharmaceutical company’s stock after selling 39,739 shares during the quarter. Rhumbline Advisers owned 0.19% of Gilead Sciences worth $214,631,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in GILD. FMR LLC grew its holdings in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP grew its stake in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Gilead Sciences by 723.3% during the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after acquiring an additional 5,653,075 shares during the period. Point72 Asset Management L.P. increased its position in shares of Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after acquiring an additional 1,793,145 shares during the period. Finally, International Assets Investment Management LLC boosted its holdings in shares of Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after purchasing an additional 1,622,806 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on GILD shares. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday. Daiwa America upgraded Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Bank of America reiterated a “buy” rating and set a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, UBS Group increased their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $101.33.

Gilead Sciences Trading Down 1.8 %

Shares of Gilead Sciences stock opened at $104.08 on Friday. The firm’s 50 day simple moving average is $93.63 and its two-hundred day simple moving average is $87.37. The firm has a market capitalization of $129.71 billion, a price-to-earnings ratio of 1,156.44, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $106.69. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Analysts predict that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.04%. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 137,676 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the completion of the sale, the chief financial officer now directly owns 171,223 shares of the company’s stock, valued at approximately $17,502,415.06. This represents a 44.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 710,500 shares of company stock valued at $67,684,956 over the last quarter. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.